Background: The skin is a protective barrier of the body against external factors, and its damage leads to a loss of integrity. Normal wound healing results in a correct, flat, bright, and flexible scar. Initial skin damage and patient specific factors in wound healing contribute that many of these scars may progress into widespread or pathologic hypertrophic and keloid scars. The changes in cosmetic appearance, continuing pain, and loss of movement due to contracture or adhesion and persistent pruritis can significantly affect an individual's quality of life and psychological recovery post injury. Many different treatment methods can reduce the trauma and surgical scars. Manual scar treatment includes various techniques of therapy. The most effectiveness is a combined therapy, which has a multidirectional impact. Clinical observations show an effectiveness of manual scar therapy. Material and methods: The aim of this work was to evaluate effectiveness of the scar manual therapy combined with complementary methods on the postoperative scars. Treatment protocol included two therapies during 30 min per week for 8 weeks. Therapy included manual scar manipulation, massage, cupping, dry needling, and taping. Results: Treatment had a significant positive effect to influence pain, pigmentation, pliability, pruritus, surface area, and scar stiffness. Improvement of skin parameters (scar elasticity, thickness, regularity, color) was also noticed. Conclusion: To investigate the most effective manual therapy strategy, further studies are needed, evaluating comparisons of different individual and combined scar therapy modalities.
Betulin is a lupane-type pentacyclic triterpene. It is characterized by a range of biological properties, including anti-cancer and anti-inflammatory activities. It is also an origin compound for obtaining derivatives with higher biological activity and better bioavailability. Chronic inflammation stimulates the formation of a pro-cancer microenvironment, promoting tumor growth, cell migration, and neoangiogenesis. Many factors, immune system cells, and cytokines and chemokines released by them are involved in this process. Therefore, it has been suggested that the optimal target for anti-cancer drugs in this disease could be substances showing anti-inflammatory activity. The aim of the study was to indicate the direction of changes in the expression of genes related to the inflammatory state in colorectal cancer cells promoted by betulin and its selected alkynyl derivatives. Cytotoxicity assessment was carried out using a sulforhodamine B (SRB) test, whereas lipophilicity was determined by reversed-phase thin-layer chromatography (RP-TLC). The analysis of the gene expression profile in colon adenocarcinoma cells treated with betulin and its derivatives was performed using oligonucleotide microarrays HG-U133A. Based on the conducted analysis, it can be stated that betulin and its derivatives 1–3 influence the change in the expression profile of genes related to inflammatory processes in the HT-29 colon adenocarcinoma cell lines. The highest expression changes (FC > 2) were observed for HMOX1 (compound 1 vs. control) and TMED7 (compound 3 vs. control) mRNAs. An important observation is the comparison of the profile of changes in the expression of the studied genes in the compared compounds. Derivative 1 showed the greatest similarity to control cells, whereas betulin showed similarity to cisplatin. These observations indicate the necessity further research on the impact of betulin and its derivatives on inflammatory processes and the possible direction of chemical modification of compounds.
Background: Melasma is a chronic hyperpigmentation disorder, often therapy-resistant. Minimally invasive combinations of chemical stimulators and serums show promise. This study evaluated trichloroacetic acid stabilized with hydrogen peroxide and kojic acid, plus a serum with niacinamide, tranexamic acid, lactoferrin, ferulic acid, alpha-lipoic acid, and physic acid. Methods: Ten female volunteers with clinically diagnosed melasma underwent six treatment sessions. Each procedure involved application of the chemical stimulator followed by the serum, with strict photoprotection advised. Clinical improvement was assessed using the modified Melasma Area and Severity Index (mMASI) by three independent experts. Objective analysis of pigmentation and texture was performed with photographic documentation processed by the Grey Level Co-Occurrence Matrix (GLCM), measuring contrast and homogeneity in selected facial regions. Results: After six treatments, significant improvement was observed. Mean mMASI scores decreased by 62.3% after 2 weeks and 62.9% after 8 weeks. GLCM confirmed pigmentation reduction, showing decreased contrast and increased homogeneity across all regions, with the chin responding best. Correlation analysis indicated a positive trend between mMASI reduction and contrast changes. No serious adverse events or post-inflammatory hyperpigmentation were reported. Conclusions: The combined protocol significantly reduced melasma hyperpigmentation both clinically and objectively. GLCM analysis complements traditional scales and may provide a valuable quantitative tool for future research.